A protein that drives growth of pancreatic cancer, and which could be a target for new treatments, has been identified by researchers at the Crick.
The study, published in Nature Cell Biology, looked into the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma. This is an aggressive cancer that develops from secretory and tubular cells of the pancreas.
There are no effective therapies to treat this cancer and only 8% of patients survive beyond five years after diagnosis.
These cells are vital to pancreatic cancer and if even just a few of them survive chemotherapy, the cancer is able to bounce back.
The researchers analysed a specific group of tumour cells, called cancer stem cells. Similar to how healthy human stem cells repair tissues and organs, these cells have the ability to start new tumours and they can also differentiate into different types of tumour cells.
As these cells are a driving force behind cancer growth, being able to identify if they are present is an important step towards the development of new treatments. By analysing the gene expression of these cancer stem cells, the team found that a protein, called CD9, is present on their surface both when the tumour is developing and when it is more established. This protein could therefore be used as a marker to help locate these cells.
The study further established that this protein is not just a marker of cancer stem cells, but also promotes their malignant behaviour. The researchers altered the amount of CD9 in tumour cells in mice and found that when the levels of this protein were reduced, smaller tumours formed. Conversely, increasing levels of CD9 made cancer cells more aggressive and able to form large tumours quickly.
These findings were supported by existing clinical data showing that patients whose tumour cells have more CD9 have a poorer clinical prognosis. About 10% of people with this type of cancer have amplified levels of CD9.
“These cells are vital to pancreatic cancer and if even just a few of them survive chemotherapy, the cancer is able to bounce back. We need to find effective ways to remove these cells, and so stop them from fuelling cancer growth. However, we need more experiments to validate the importance of CD9 in human pancreatic cancer,” says Victoria Wang, lead author and member of the Adult Stem Cell Laboratory at the Crick.
To understand the mechanism behind how CD9 bolsters cancer, the team looked into the cancer stem cells’ metabolism. Their findings showed that CD9 increases the rate cells take up glutamine, an amino acid which helps provide energy for the cancer to grow.
“Now we know this protein is both linked to cancer stem cells and helps cancer growth, this could guide the development of new treatments that are targeted at the protein and so cut off the supply of glutamine to cancer stem cells, effectively starving the cancer,” says Axel Behrens, corresponding author and group leader in the Adult Stem Cell Laboratory at the Crick.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Canceron October 7, 2020 at 5:04 am
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today ...
- NantKwest/ImmunityBio expand mid-stage pancreatic cancer studyon October 6, 2020 at 6:27 pm
NantKwest (NASDAQ:NK) and its collaborating partner ImmunityBio have announced to add a third cohort to ongoing Phase 2 immunotherapy trial for locally advanced or metastatic pancreatic cancer, and ...
- Yale cancer receives ACGT grant to advance strategies for treating pancreatic canceron October 6, 2020 at 6:40 am
Alliance for Cancer Gene Therapy (ACGT) gives $500,000 research grant to Sidi Chen, Ph.D., with Yale School of Medicine and Yale Cancer Center to advance strategies for treating pancreatic cancer ...
- Bob Gibson, the St. Louis Cardinals' dominating Hall of Fame pitcher, has died at 84 after fighting pancreatic canceron October 3, 2020 at 1:57 am
Bob Gibson, the St. Louis Cardinals' dominating Hall of Fame pitcher, has died at 84 after fighting pancreatic cancer ...
- Hall of Famer, Cardinals legend Bob Gibson dies at 84 after battle with pancreatic canceron October 2, 2020 at 8:32 pm
Gibson becomes the second Cardinals Hall of Famer to die in the last month along with Lou Brock who died September 6.
- LI's pancreatic cancer walk goes virtual during pandemicon October 1, 2020 at 1:31 pm
When the 20th Long Island Walk for Pancreatic Cancer Research steps off this weekend, a very special survivor will be leading the way virtually. Joel Evans, 72, a Commack resident who is a five-year p ...
- Nonprofit Raises $1 Million for Pancreatic Cancer Researchon September 30, 2020 at 5:38 am
Sept. 20, nonprofit Purple Pansies received more than $1 million in donations to help end pancreatic cancer in their ...
- Competitive Scenario of Pancreatic Cancer Treatment Drugs Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025on September 29, 2020 at 11:58 pm
Global ""Pancreatic Cancer Treatment Drugs Market""(2020-2026) status and position of worldwide and key regions, ...
- Hackensack Meridian CDI Scientists Find One-Two Punch Working Against Stubborn Pancreatic Cancer in Preclinical Modelson September 29, 2020 at 6:50 am
PRNewswire/ -- A one-two punch of changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of ...
- What coverage does Medicare provide for pancreatic cancer?on September 29, 2020 at 4:53 am
Medicare covers many treatments and services related to pancreatic cancer. Out-of-pocket costs may apply. Read on for more information.
via Bing News